Prostaglandin D₂ receptor antagonists in allergic disorders: safety, efficacy, and future perspectives

References

• Holgate ST, Broide D. New targets for allergic rhinitis--a disease of civilization. Nat Rev Drug Discov. 2003;2:902–914.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56.
   PubMed Web of Science ®Google Scholar
• Law AW, Reed SD, Sundy JS, et al. Direct costs of allergic rhinitis in the United States: estimates from the 1996 medical expenditure panel survey. J Allergy Clin Immunol. 2003;111:296–300.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Senna G, Mitchell PD, et al. Therapeutic interventions in severe asthma. World Allergy Organ J. 2016;9:40.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133:921–923.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38:2058–2070 e1.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;2475–2485.
   Web of Science ®Google Scholar
• Sandham DA, Arnold N, Aschauer H, et al. Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013;21:6582–6591.
   PubMed Web of Science ®Google Scholar
• Claar D, Hartert TV, Peebles RS Jr. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med. 2015;9:55–72.
   PubMed Web of Science ®Google Scholar
• Baothman BK, Smith J, Kay LJ, et al. Prostaglandin D2 generation from human lung mast cells is catalysed exclusively by cyclooxygenase-1. Eur J Pharmacol. 2018;819:225–232.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol. 1982;129:1627–1631.
   PubMed Web of Science ®Google Scholar
• Peters SP, MacGlashan DW Jr., Schulman ES, et al. Arachidonic acid metabolism in purified human lung mast cells. J Immunol. 1984;132:1972–1979.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Burns GB, Robinson C, et al. Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol. 1984;133:2138–2144.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1566–1576 e5.
   PubMed Web of Science ®Google Scholar
• Monneret G, Li H, Vasilescu J, et al. 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol. 2002;168:3563–3569.
   PubMed Web of Science ®Google Scholar
• Heinemann A, Schuligoi R, Sabroe I, et al. Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol. 2003;170:4752–4758.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders and cancer. Front Immunol. 2018;9:1595.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Mato N, Hagiwara K, et al. The pathogenicity of IL-33 on steroid-resistant eosinophilic inflammation via the activation of memory-type ST2+ CD4+ T cells. Send J Leukoc Biol. 2018;104:895–901.
   PubMed Web of Science ®Google Scholar
• Urade Y, Ujihara M, Horiguchi Y, et al. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol. 1989;143:2982–2989.
   PubMed Web of Science ®Google Scholar
• Tajima T, Murata T, Aritake K, et al. Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and prostaglandin E(2). J Pharmacol Exp Ther. 2008;326:493–501.
   PubMed Web of Science ®Google Scholar
• Luna-Gomes T, Magalhaes KG, Mesquita-Santos FP, et al. Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation. J Immunol. 2011;187:6518–6526.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ogawa K, Sugamura K, et al. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol. 2000;164:2277–2280.
   PubMed Web of Science ®Google Scholar
• Camacho M, Lopez-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res. 1998;83:353–365.
   PubMed Web of Science ®Google Scholar
• Taba Y, Sasaguri T, Miyagi M, et al. Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase expression in vascular endothelial cells. Circ Res. 2000;86:967–973.
   PubMed Web of Science ®Google Scholar
• Mahmud I, Ueda N, Yamaguchi H, et al. Prostaglandin D synthase in human megakaryoblastic cells. J Biol Chem. 1997;272:28263–28266.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Watanabe K, Kanaoka Y, et al. Induction of hematopoietic prostaglandin D synthase in human megakaryocytic cells by phorbol ester. Biochem Biophys Res Commun. 1997;241:288–293.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Budelsky AL. Prostaglandin D(2) receptor CRTH2 antagonists for the treatment of inflammatory diseases. Prog Med Chem. 2011;50:49–107.
   PubMedGoogle Scholar
• Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153(Suppl 1):S191–9.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Shichijo M, Ikeda M, et al. Prostanoid DP receptor antagonists suppress symptomatic asthma-like manifestation by distinct actions from a glucocorticoid in rats. Eur J Pharmacol. 2011;666:233–241.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov. 2007;6:313–325.
   PubMed Web of Science ®Google Scholar
• Moon TC, Campos-Alberto E, Yoshimura T, et al. Expression of DP2 (CRTh2), a prostaglandin D(2) receptor, in human mast cells. PLoS One. 2014;9:e108595.
   PubMed Web of Science ®Google Scholar
• Oguma T, Asano K, Ishizaka A. Role of prostaglandin D(2) and its receptors in the pathophysiology of asthma. Allergol Int. 2008;57:307–312.
   PubMedGoogle Scholar
• Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255–261.
   PubMed Web of Science ®Google Scholar
• Stubbs VE, Schratl P, Hartnell A, et al. Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem. 2002;277:26012–26020.
   PubMed Web of Science ®Google Scholar
• Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, et al. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy. 2004;34:1283–1290.
   PubMed Web of Science ®Google Scholar
• Monneret G, Boumiza R, Gravel S, et al. Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils. J Pharmacol Exp Ther. 2005;312:627–634.
   PubMed Web of Science ®Google Scholar
• Virgolini I, Li S, Sillaber C, et al. Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. J Biol Chem. 1992;267:12700–12708.
   PubMed Web of Science ®Google Scholar
• Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108:982–988.
   PubMed Web of Science ®Google Scholar
• Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001;98:1942–1948.
   PubMed Web of Science ®Google Scholar
• Wojno ED, Monticelli LA, Tran SV, et al. The prostaglandin D(2) receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol. 2015;8:1313–1323.
   PubMed Web of Science ®Google Scholar
• Xue L, Salimi M, Panse I, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol. 2014;133:1184–1194.
   PubMed Web of Science ®Google Scholar
• Jandl K, Stacher E, Balint Z, et al. Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung. J Allergy Clin Immunol. 2016;137:833–843.
   PubMed Web of Science ®Google Scholar
• Gosset P, Bureau F, Angeli V, et al. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J Immunol. 2003;170:4943–4952.
   PubMed Web of Science ®Google Scholar
• Frankenberger M, Hofer TP, Marei A, et al. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint. Eur J Immunol. 2012;42:957–974.
   PubMed Web of Science ®Google Scholar
• Stinson SE, Amrani Y, Brightling CE. D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells. J Allergy Clin Immunol. 2015;135:395–406.
   PubMed Web of Science ®Google Scholar
• Kanai K, Okano M, Fujiwara T, et al. Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts. Allergol Int. 2016;65:414–419.
   PubMed Web of Science ®Google Scholar
• Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85:372–382.
   PubMed Web of Science ®Google Scholar
• Marone G, Borriello F, Varricchi G, et al. Basophils: historical reflections and perspectives. Chem Immunol Allergy. 2014;100:172–192.
   PubMedGoogle Scholar
• Bradding P, Arthur G. Mast cells in asthma--state of the art. Clin Exp Allergy. 2016;46:194–263.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Raap U, Rivellese F, et al. Human mast cells and basophils-How are they similar how are they different? Immunol Rev. 2018;282:8–34.
   PubMed Web of Science ®Google Scholar
• Rivellese F, Nerviani A, Rossi FW, et al. Mast cells in rheumatoid arthritis: friends or foes? Autoimmun Rev. 2017;16:557–563.
   PubMed Web of Science ®Google Scholar
• Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749–786.
   PubMed Web of Science ®Google Scholar
• Piliponsky AM, Romani L. The contribution of mast cells to bacterial and fungal infection immunity. Immunol Rev. 2018;282:188–197.
   PubMed Web of Science ®Google Scholar
• Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardiometabolic diseases. Nat Rev Cardiol. 2015;12:643–658.
   PubMed Web of Science ®Google Scholar
• Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971–978.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.
   PubMed Web of Science ®Google Scholar
• Marone G, Varricchi G, Loffredo S, et al. Are basophils and mast cells masters in HIV infection? Int Arch Allergy Immunol. 2016;171:158–165.
   PubMed Web of Science ®Google Scholar
• Korosec P, Gibbs BF, Rijavec M, et al. Important and specific role for basophils in acute allergic reactions. Clin Exp Allergy. 2018;48:502–512.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kagey-Sobotka A, MacGlashan DW Jr., et al. Effect of prostaglandin D2 in modulating histamine release from human basophils. J Pharmacol Exp Ther. 1984;228:400–406.
   PubMed Web of Science ®Google Scholar
• Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986;315:800–804.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Dixon CM, Dollery CT, et al. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis. 1986;133:252–254.
   PubMedGoogle Scholar
• Liu MC, Bleecker ER, Lichtenstein LM, et al. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis. 1990;142:126–132.
   PubMed Web of Science ®Google Scholar
• Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med. 2011;183:299–309.
   PubMed Web of Science ®Google Scholar
• Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131:1504–1512.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Westcott JY, Smith HR, et al. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis. 1989;139:450–457.
   PubMed Web of Science ®Google Scholar
• Schulman ES, Newball HH, Demers LM, et al. Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis. 1981;124:402–406.
   PubMed Web of Science ®Google Scholar
• Spik I, Brenuchon C, Angeli V, et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol. 2005;174:3703–3708.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Harker J, Borriello F, et al. T follicular helper (Tfh) cells in normal immune responses and in allergic disorders. Allergy. 2016;71:1086–1094.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.
   PubMed Web of Science ®Google Scholar
• Xue L, Barrow A, Pettipher R. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol. 2009;156:126–133.
   PubMed Web of Science ®Google Scholar
• Bohm E, Sturm GJ, Weiglhofer I, et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem. 2004;279:7663–7670.
   PubMedGoogle Scholar
• Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459:195–199.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7:e1393134.
   PubMed Web of Science ®Google Scholar
• Borriello F, Granata F, Varricchi G, et al. Immunopharmacological modulation of mast cells. Curr Opin Pharmacol. 2014;17:45–57.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Adkinson NF Jr., Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest. 1985;76:2247–2253.
   PubMed Web of Science ®Google Scholar
• Wagenmann M, Baroody FM, Desrosiers M, et al. Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. Clin Exp Allergy. 1996;26:371–378.
   PubMed Web of Science ®Google Scholar
• Small P, Biskin N, Barrett D. Effects of intensity of early response to allergen on the late phase of both the nose and skin. Ann Allergy. 1994;73:252–258.
   PubMedGoogle Scholar
• Horak F, Toth J, Hirschwehr R, et al. Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patients. Allergy. 1998;53:68–72.
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Depre M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol. 2007;63:135–141.
   PubMed Web of Science ®Google Scholar
• Nantel F, Fong C, Lamontagne S, et al. Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat. 2004;73:87–101.
   PubMed Web of Science ®Google Scholar
• Nagira Y, Goto K, Tanaka H, et al. Prostaglandin D2 modulates neuronal excitation of the trigeminal ganglion to augment allergic rhinitis in guinea pigs. J Pharmacol Exp Ther. 2016;357:273–280.
   PubMed Web of Science ®Google Scholar
• White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018;27:199–207.
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Kuna P. Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs. 2017;77:1281–1294.
   PubMed Web of Science ®Google Scholar
• Singh D, Ravi A, Southworth T. CRTH2 antagonists in asthma: current perspectives. Clin Pharmacol. 2017;9:165–173.
   PubMed Web of Science ®Google Scholar
• Santini G, Mores N, Malerba M, et al. Investigational prostaglandin D2 receptor antagonists for airway inflammation. Expert Opin Investig Drugs. 2016;25:639–652.
   PubMed Web of Science ®Google Scholar
• Farne H, Jackson DJ, Johnston SL. Are emerging PGD2 antagonists a promising therapy class for treating asthma? Expert Opin Emerg Drugs. 2016;21:359–364.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D. Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma. Expert Opin Investig Drugs. 2016;25:1083–1092.
   PubMed Web of Science ®Google Scholar
• Norman P. Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014;23:55–66.
   PubMed Web of Science ®Google Scholar
• Takahashi G, Asanuma F, Suzuki N, et al. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015;765:15–23.
   PubMed Web of Science ®Google Scholar
• Okubo K, Hashiguchi K, Takeda T, et al. A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis. Allergy. 2017;72:1565–1575.
   PubMed Web of Science ®Google Scholar
• Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008;83:840–847.
   PubMed Web of Science ®Google Scholar
• Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009;124:942–8 e1–9.
   Web of Science ®Google Scholar
• Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2013;131:339–345.
   PubMed Web of Science ®Google Scholar
• Nagata N, Iwanari H, Kumagai H, et al. Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2. PLoS One. 2017;12:e0175452.
   PubMed Web of Science ®Google Scholar
• Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44:1044–1052.
   PubMed Web of Science ®Google Scholar
• Ratner P, Andrews CP, Hampel FC, et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma Clin Immunol. 2017;13:18.
   PubMed Web of Science ®Google Scholar
• Gehin M, Strasser DS, Zisowsky J, et al. A novel CRTH2 antagonist: single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects. J Clin Pharmacol. 2015;55:787–797.
   PubMed Web of Science ®Google Scholar
• Fitzgerald MF, Whitmarsh M, Prosser J, et al. The in vitro profile of ADC3680, A potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma. Am J Respir Crit Care Med. 2013;187:A2617.
   Web of Science ®Google Scholar
• Fitzgerald M, Snape S, Febbraro S, et al. The safety, PK, PD profile of AD3680, a potent and selective CRTH2 antagonist in healthy volunteers and partly controlled atopic asthmatic subjects. C-23 Novel therapeutic in asthma. ATS Conference Proceedings, Pennsylvania. 2013;A3874.
   Google Scholar
• Bain G, Lorrain DS, Stebbins KJ, et al. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011;338:290–301.
   PubMed Web of Science ®Google Scholar
• Bain G, King CD, Brittain J, et al. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2. J Clin Pharmacol. 2012;52:1482–1493.
   PubMed Web of Science ®Google Scholar
• Norman P. A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011;21:1931–1936.
   PubMed Web of Science ®Google Scholar
• Bell S, Neitzel A, Nugent C, et al. Arry-502: safety, Pk and Pd of the Crth2 antagonist in healthy subjects following repeat dose administration. Am J Respir Crit Care Med. 2012;185:A2756.
   Google Scholar
• Wenzel SE, Saunders M, Chantry D, et al. Safety and efficacy of ARRY-502, a potent, selective, oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma. J Allergy Clin Immunol. 2014;133:AB4.
   Web of Science ®Google Scholar
• Shiraishi Y, Takeda K, Domenico J, et al. Role of prostaglandin D2 and CRTH2 blockade in early- and late-phase nasal responses. Clin Exp Allergy. 2014;44:1076–1082.
   PubMed Web of Science ®Google Scholar
• Tasaki M, Kobayashi M, Tenda Y, et al. Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of “chemoattractant receptor homologous molecule expressed on Th2 cells” (CRTH2). Eur J Pharm Sci. 2013;49:434–440.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bjermer L, Tornling G. Two phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther. 2016;10:2759–2770.
   PubMed Web of Science ®Google Scholar
• Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419–431.
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133:414–419.
   PubMed Web of Science ®Google Scholar
• Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44.
   PubMed Web of Science ®Google Scholar
• Fowler A, Koenen R, Hilbert J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel CRTH2 antagonist BI 1021958 at single oral doses in healthy men and multiple oral doses in men and women with well-controlled asthma. J Clin Pharmacol. 2017;57:1444–1453.
   PubMed Web of Science ®Google Scholar
• Sykes DA, Bradley ME, Riddy DM, et al. Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. Mol Pharmacol. 2016;89:593–605.
   PubMed Web of Science ®Google Scholar
• Erpenbeck VJ, Vets E, Gheyle L, et al. Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers. Clin Pharmacol Drug Dev. 2016;5:306–313.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4:699–707.
   PubMed Web of Science ®Google Scholar
• Erpenbeck VJ, Popov TA, Miller D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther. 2016;39:54–63.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50:pii1700670.
   Web of Science ®Google Scholar
• Calbet M, Andres M, Armengol C, et al. Pharmacological characterization of CRTh2 antagonist LAS191859: long receptor residence time translates into long-lasting in vivo efficacy. Pharmacol Res. 2016;111:208–216.
   PubMed Web of Science ®Google Scholar
• Gallant M, Beaulieu C, Berthelette C, et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011;21:288–293.
   PubMed Web of Science ®Google Scholar
• Gervais FG, Sawyer N, Stocco R, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol. 2011;79:69–76.
   PubMed Web of Science ®Google Scholar
• Mauser PJ, House A, Jones H, et al. Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged brown norway rats. Pulm Pharmacol Ther. 2013;26:677–684.
   PubMed Web of Science ®Google Scholar
• Gil MA, Caniga M, Woodhouse JD, et al. Anti-inflammatory actions of chemoattractant receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of alternaria alternata elicited pulmonary inflammation. Eur J Pharmacol. 2014;743:106–116.
   PubMed Web of Science ®Google Scholar
• Wang YH, Trucksis M, McElwee JJ, et al. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012;92:96–102.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther. 2012;340:473–482.
   PubMed Web of Science ®Google Scholar
• Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42:38–48.
   PubMed Web of Science ®Google Scholar
• Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46–52.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69:1223–1232.
   PubMed Web of Science ®Google Scholar
• Liu J, Li AR, Wang Y, et al. Discovery of AMG 853, a CRTH2 and DP Dual Antagonist. ACS Med Chem Lett. 2011;2:326–330.
   PubMed Web of Science ®Google Scholar
• Staiano RI, Loffredo S, Borriello F, et al. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol. 2016;99:531–540.
   PubMed Web of Science ®Google Scholar
• Ferrando M, Bagnasco D, Varricchi G, et al. Personalized Medicine in Allergy. Allergy Asthma Immunol Res. 2017;9:15–24.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–338.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16:186–200.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Caminati M, et al. Targeting interleukin-5 or interleukin-5Ralpha: safety considerations. Drug Saf. 2017;40:559–570.
   PubMed Web of Science ®Google Scholar
• Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159–170.e2.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572–1579.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lee PH, Chaffin MD, et al. A genome-wide cross-trait analysis from UK biobank highlights the shared genetic architecture of asthma and allergic diseases. Nat Genet. 2018;50:857–864.
   PubMed Web of Science ®Google Scholar
• Parulekar AD, Diamant Z, Hanania NA. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017;23:3–11.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Loffredo S, Galdiero MR, et al. Innate effector cells in angiogenesis and lymphangiogenesis. Curr Opin Immunol. 2018;53:152–160.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Emergence of biomolecular pathways to define novel asthma phenotypes. type-2 immunity and beyond. Am J Respir Cell Mol Biol. 2016;55:1–4.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170:122–131.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Controversial role of mast cells in skin cancers. Exp Dermatol. 2017;26:11–17.
   PubMed Web of Science ®Google Scholar
• Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017;8:CD005603.
   PubMedGoogle Scholar
• Su MW, Lin WC, Tsai CH, et al. Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression. Allergy. 2018;73:2024–2032.
   PubMed Web of Science ®Google Scholar
• James KM, Gebretsadik T, Escobar GJ, et al. Risk of childhood asthma following infant bronchiolitis during the respiratory syncytial virus season. J Allergy Clin Immunol. 2013;132:227–229.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667–672.
   PubMed Web of Science ®Google Scholar
• Werder RB, Lynch JP, Simpson JC, et al. PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-lambda production. Sci Transl Med. 2018;10:eaao0052.
   Web of Science ®Google Scholar
• Carretero R, Sektioglu IM, Garbi N, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609–617.
   PubMed Web of Science ®Google Scholar
• Lucarini V, Ziccheddu G, Macchia I, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017;6:e1317420.
   PubMed Web of Science ®Google Scholar
• Zhang B, Bie Q, Wu P, et al. PGD2/PTGDR2 signaling restricts the self-renewal and tumorigenesis of gastric cancer. Stem Cells. 2018;36:990–1003.
   Web of Science ®Google Scholar
• Chu C, Wei H, Zhu W, et al. Decreased prostaglandin D2 levels in major depressive disorder are associated with depression-like behaviors. Int J Neuropsychopharmacol. 2017;20:731–739.
   PubMed Web of Science ®Google Scholar